1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Biologics Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Source
6.1 Microbial
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Mammalian
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Others
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by Product
7.1 Monoclonal Antibodies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Vaccines
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Recombinant Proteins
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Antisense, RNAi and Molecular Therapy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by Disease
8.1 Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Immunological Disorders
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Cardiovascular Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Hematological Disorders
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast
9 Market Breakup by Manufacturing
9.1 Outsourced
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 In-House
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 AbbVie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Amgen Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 AstraZeneca plc
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche Ltd
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 GlaxoSmithKline plc
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanofi
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
世界の生物製剤市場予測2023年-2028年 |
| 【英語タイトル】Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 | |
 | ・商品コード：IMARC23AP134 ・発行会社（調査会社）：IMARC ・発行日：2023年3月2日 ・ページ数：146 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医療 |
| Single User | USD2,999 ⇒換算￥455,848 | 見積依頼/購入/質問フォーム |
| Five User | USD3,999 ⇒換算￥607,848 | 見積依頼/購入/質問フォーム |
| Enterprisewide | USD4,999 ⇒換算￥759,848 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| IMARC社の本調査レポートでは、2022年に3,210億ドルであった世界の生物製剤市場規模が、2028年までに5,355億ドルに拡大し、予測期間中にCAGR8.1%で成長すると予想しています。本書は、生物製剤の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、ソース別（微生物、哺乳類、その他）分析、製品別（モノクローナル抗体、ワクチン、リコンビナントタンパク質、アンチセンス・RNAi・分子療法、その他）分析、疾患別（腫瘍、免疫疾患、心血管系疾患、血液疾患、その他）分析、製造別（アウトソーシング、インハウス）分析、地域別（北米、アジア太平洋、ヨーロッパ、中南米、中東・アフリカ）分析、SWOT分析、バリューチェーン分析、ポーターズファイブフォース分析、価格分析、競争状況などの項目を整理しています。また、本書には、AbbVie Inc.、Amgen Inc.、AstraZeneca plc、F. Hoffmann-La Roche Ltd、GlaxoSmithKline plc、Johnson & Johnson、Merck KGaA、Novartis AG、Pfizer Inc. and Sanofi.などの企業情報が含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の生物製剤市場規模：ソース別 - 微生物由来製剤の市場規模 - 哺乳類由来製剤の市場規模 - その他の市場規模 ・世界の生物製剤市場規模：製品別 - モノクローナル抗体の市場規模 - ワクチンの市場規模 - リコンビナントタンパク質の市場規模 - アンチセンス・RNAi・分子療法の市場規模 - その他の市場規模 ・世界の生物製剤市場規模：疾患別 - 腫瘍における市場規模 - 免疫疾患における市場規模 - 心血管系疾患における市場規模 - 血液疾患における市場規模 - その他における市場規模 ・世界の生物製剤市場規模：製造別 - アウトソーシングにおける市場規模 - インハウスにおける市場規模 ・世界の生物製剤市場規模：地域別 - 北米の生物製剤市場規模 - アジア太平洋の生物製剤市場規模 - ヨーロッパの生物製剤市場規模 - 中南米の生物製剤市場規模 - 中東・アフリカの生物製剤市場規模 ・SWOT分析 ・バリューチェーン分析 ・ポーターズファイブフォース分析 ・価格分析 ・競争状況 |
The global biologics market size reached US$ 321.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 535.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.
Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms. These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases.
Biologics Market Trends:
The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19). Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn’s diseases.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biologics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on source, product, disease and manufacturing.
Breakup by Source:
Microbial
Mammalian
Others
Breakup by Product:
Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others
Breakup by Disease:
Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others
Breakup by Manufacturing:
Outsourced
In-House
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi.
Key Questions Answered in This Report
1. What was the size of the global biologics market in 2022?
2. What is the expected growth rate of the global biologics market during 2023-2028?
3. What are the key factors driving the global biologics market?
4. What has been the impact of COVID-19 on the global biologics market?
5. What is the breakup of the global biologics market based on the source?
6. What is the breakup of the global biologics market based on the product?
7. What is the breakup of the global biologics market based on the disease?
8. What is the breakup of the global biologics market based on the manufacturing?
9. What are the key regions in the global biologics market?
10. Who are the key players/companies in the global biologics market?
❖ レポートの目次 ❖
| ★調査レポート[世界の生物製剤市場予測2023年-2028年] (コード：IMARC23AP134)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の生物製剤市場予測2023年-2028年]についてメールでお問い合わせ |
